Key Developments For inVentiv Health, Inc.
inVentiv Health, Inc. (VTIV.O) (Nasdaq)
Millennium Biotechnologies Group, Inc. Announces Agreement With inVentiv Health Inc.'s inVentiv Advance Insights To Promote Resurgex Essential To Long Term Care Market
Millennium Biotechnologies Group, Inc. announced that it has entered into a three-year exclusive agreement with inVentiv Advance Insights, a division of inVentiv Health Inc., for the promotion of its Resurgex Essential line of nutritional supplements into the long-term care market. Concurrently, inVentiv has significantly reduced its secured position to $510,000 of which it has received $110,000 and warrants in Millennium Biotechnologies with a $0.20 strike price.
Star Scientific, Inc Chooses InVentiv Health, Inc. To Market Nutraceutique CigRx
Star Scientific, Inc. announced that it chose InVentiv Health, Inc. to market its product Nutraceutique CigRx which is manufactured by Rock Creek Pharmaceuticals, a subsidiary of the Company. Financial details of the agreement were not disclosed.
inVentiv Health Inc. Announces Terrell Herring Resigning As President And Chief Operating Officer-Knobias
Knobias reported that inVentiv Health Inc.'s Terrell Herring will resign as President and Chief Operating Officer of inVentiv Health effective December 31, 2009. He will continue in his position as a Director on inVentiv Health's Board of Directors.
inVentiv Health Inc. Announces Resignation Of Terrell Herring As President
inVentiv Health Inc. announced that Terrell Herring will resign as President and Chief Operating Officer (COO) of inVentiv Health effective December 31, 2009.
inVentiv Health Inc. Issues Q3 2009 EPS Outlook Below Analysts' Estimates; Reaffirms FY 2009 Outlook
inVentiv Health Inc. announced that for the third quarter 2009, it expects earnings per share (EPS) target of $0.30 to $0.32. The Company is reconfirming its fiscal 2009 revenue target of $1.1 billion to $1.2 billion and its EPS target of $1.30 to $1.40. According to Reuters Estimates, analysts were expecting the Company to report EPS of $0.37 for the third quarter 2009; EPS of $1.35 for fiscal 2009.
